药物发现和开发的基本原则

关键字：类型：

下载页码(大于0,小于537)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)

microsomal stability

permeability. See Permeability

plasma protein binding, 268–270,269f–270f 268 270 269 270

solubility, 250–254, 250f–254f 250 254 250 254

transporters, 266–268, 268f 266 268 268

Acetylcholine-binding protein (AChBP),121, 122f 121 122

α1-Acid glycoprotein (AGP), 268–269 268 269

Acquired immune deficiency syndrome (AIDS), 1 1

diagnoses annual report, 506–507, 507f 506 507 507

Active transport mode, 255, 255f 255 255

Adenosine-5′-triphosphate (ATP), 99–101,102f 99 101 102

ADME. See Absorption, distribution,

metabolism, and excretion (ADME)

Aequorin-based assay systems, 178–180 178 180

Agonists, 112–114, 113f, 150, 150f 112 114 113 150 150

CB2 agonists, 282 282

CFP fluorescence, 170–171 170 171

GPCR activation, 174–175, 174f 174 175 174

nAChR, 121 121

μ-opioid receptor, 16–18, 17f, 209–210,517–518 16 18 17 209 210 517 518

Allosteric inhibitors, 103f, 104 103 104

Ames assay, 356–357, 357f 356 357 357

γ-Aminobutyric acid (GABA), 122–123, 123f 122 123 123

Amiodarone, 116, 116f 116 116

Amplified luminescent proximity

homogeneous assay (AlphaScreen™), 175–177,175f–177f 175 177 175 177

Amyotrophic lateral sclerosis (ALS), 15,310–311, 346 15 310 311 346

Anacetrapib (MK-0859), 12, 12f 12 12

Animal models, disease states

cardiovascular disease animal model, 323 323

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：